{"disease":{"id":"high-risk-oral-precancerous-disease","name":"high risk oral precancerous disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05463796","title":"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06623110","title":"Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Glenn J. Hanna","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}